Biogen announced that the high dose regimen of nusinersen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
We are delighted to invite you to read the latest article on our Clinical Trials Finder website by SMA News Today.
We are delighted to invite you to read the latest article on our Clinical Trials Finder website by Rare Revolution Magazine.
Today, Biogen announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for its supplemental New Drug Application for a high-dose regimen of nusinersen in the treatment of SMA.